Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Sep;32(9):e70061.
doi: 10.1111/jvh.70061.

Clinical Observational Study on HBV Reactivation After Direct-Acting Antiviral Therapy in HCV/HBV Coinfected Patients in Guizhou, China

Mei Wang  1 , Yi Wang  2 , Zhigang Yang  1 , Changming Yang  1 , Jing Wang  1 , Huagang Xiong  1
Affiliations
Observational Study

Clinical Observational Study on HBV Reactivation After Direct-Acting Antiviral Therapy in HCV/HBV Coinfected Patients in Guizhou, China

Mei Wang et al. J Viral Hepat. 2025 Sep.

Abstract

The objective of this study is to analyse the prevalence and clinical characteristics of HCV/HBV coinfection in Guizhou, and evaluate the rate of HBV reactivation during and after anti-HCV treatment in a real-world study. This retrospective study included 1652 patients with hepatitis C virus (HCV) infection who received direct-acting antiviral (DAA) therapy at the Guiyang Public Health Clinical Center between January 2018 and December 2022 Baseline, on-treatment and posttreatment data were collected, including HCV RNA, HCV genotypes, liver function, hepatitis B virus (HBV) markers (HBsAg, HBcAb) and HBV DNA levels. The HCV/HBV coinfection rate was analysed, and the risk of HBV reactivation and disease progression following DAA therapy was assessed. Among the 1652 HCV-infected patients, the HCV/HBV coinfection rate was 49.88% (824/1652). Of these, 5.08% (84/1652) were HBsAg-positive, while 44.79% (740/1652) were HBsAg-negative/HBcAb-positive with HBV DNA < 20 IU/mL. Compared to patients with HCV monoinfection, HBsAg-positive patients had a higher proportion of males, compensated and decompensated cirrhosis, hepatocellular carcinoma (HCC) and lower platelet (PLT) counts (χ2 = 15.482, 46.101; F = 7.292; all p < 0.05). Differences in HCV genotype distribution were observed among various HBV immune status groups (χ2 = 32.529, p < 0.05). The cumulative incidence of HBV reactivation in HCV/HBV coinfected patients treated with DAAs was 1.2% (10/824). Among these, the reactivation rate was 16.67% (9/54) in HBsAg-positive patients without prophylactic anti-HBV therapy and 0.1% (1/740) in HBsAg-negative/HBcAb-positive patients. Baseline HBsAg levels were significantly higher in patients with HBV reactivation than in those without reactivation (Z = -4.291, p < 0.05). No significant changes were observed in liver function or PLT levels after HBV reactivation compared to baseline (p > 0.05), and no cases of liver failure were reported. In Guizhou, a relatively high prevalence of HBsAg-positivity and a large proportion of past HBV exposure (HBsAg-negative/HBcAb-positive, HBV DNA < 20 IU/mL) were observed among HCV-infected patients. While HBV reactivation can occur in HCV/HBV coinfected patients undergoing DAA therapy, the overall risk is low. A baseline HBsAg level > 185 IU/mL is a significant risk factor for HBV reactivation.

Keywords: DAA; coinfection; hepatitis B virus; hepatitis C virus; reactivation.

PubMed Disclaimer

References

    1. S. Y. Chen, C. F. Kao, C. M. Chen, et al., “Mechanisms for Inhibition of Hepatitis B Virus Gene Expression and Replication by Hepatitis C Virus Core Protein,” Journal of Biological Chemistry 278 (2003): 591–607.
    1. F. L. Dumoulin, A. von dem Bussche, J. Li, et al., “Hepatitis C Virus NS2 Protein Inhibits Gene Expression From Different Cellular and Viral Promoters in Hepatic and Nonhepatic Cell Lines,” Virology 305 (2003): 260–266.
    1. Y. Pan, W. Wei, L. Kang, et al., “NS5A Protein of HCV Enhances HBV Replication and Resistance to Interferon Response,” Biochemical and Biophysical Research Communications 359 (2007): 70–75.
    1. S. J. Bersoff‐Matcha, K. Cao, M. Jason, et al., “Hepatitis B Virus Reactivation Associated With Direct‐Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System,” Annals of Internal Medicine 166, no. 11 (2017): 792–798.
    1. European Association for the Study of the Liver, “EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection,” Journal of Hepatology 67, no. 2 (2017): 370–398.

Publication types

MeSH terms

LinkOut - more resources